KALV KalVista Pharmaceuticals
- 11.370
- -0.450-3.81%
- 11.370
- 0.0000.00%
KalVista Pharmaceuticals News
Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $35
Needham analyst Serge Belanger maintains $KalVista Pharmaceuticals(KALV.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41.9
Express News | Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target
KalVista Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 196.11% Needham $35 → $35 Reiterates Buy → Buy 05/03/2024 69.2% HC Wainwright & Co. $24 → $20 M
KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks
By Colin Kellaher KalVista Pharmaceuticals has filed for Food and Drug Administration approval of sebetralstat, a proposed oral on-demand treatment for hereditary-angioedema attacks in people ages 12
KalVista Submits New Drug Application For FDA Review Of Sebetralstat
Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older.The
Express News | Kalvista Pharmaceuticals Inc: Plans to Commence a Pediatric Trial (Konfident-Kid) in Q3 2024
Express News | Kalvista Pharmaceuticals Inc: Intends to Submit Additional Marketing Authorization Applications to Other Global Health Authorities Throughout 2024
Express News | Kalvista Pharmaceuticals Inc: Currently Anticipates Receiving Notification From FDA on Status of Submission in September
Express News | Kalvista Submits New Drug Application to FDA for Sebetralstat as First Oral on-Demand Treatment for Hereditary Angioedema
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Jun. 18, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and
Express News | KalVista Pharmaceuticals Presented US Subgroup Analysis From Sebetralstat Phase 3 KONFIDENT Trial, Real-world Claims And Patient Survey Data At Eastern Allergy Conference 2024, And Japanese Subgroup At Annual Meeting Of Japanese Dermatological Association
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
– US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours – – Despite growing use of long-term prophylaxis the
Sector Update: Health Care
Health care stocks rose late Friday afternoon with the NYSE Health Care Index advancing 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 0.8%. The iShares Biotechnology ETF (IBB) eased 0.1%.
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise
KalVista Pharmaceuticals (KALV) was advancing 4% Friday after the drugmaker said a late-stage trial of its candidate, sebetralstat, to treat hereditary angioedema, a swelling disorder, met primary and
Express News | KalVista Pharmaceuticals Presents Late-Breaking Phase 3 KONFIDENT Trial Data On Sebetralstat At EAACI Congress; NEJM Publication Highlights 9-Minute Median Time To Treatment And 1.3-Hour Symptom Relief For Laryngeal Attacks In KONFIDENT-S Trial
Express News | Kalvista Pharmaceuticals : Look Forward to Submitting New Drug Application for Sebetralstat to FDA in June 2024 & in EU and Japan Later This Year
Stifel Nicolaus Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People With Hereditary Angioedema
– Late-breaking data from phase 3 KONFIDENT trial of sebetralstat published in NEJM and presented concurrently at the European Academy of Allergy and Clinical Immunology Congress 2024 –– Interim data
Express News | KalVista Pharmaceuticals Says That Ten Abstracts Accepted For Presentation At The European Academy Of Allergy And Clinical Immunology Congress 2024
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing
Benjamin L Palleiko, Director, CEO, on May 17, 2024, sold 21,959 shares in Kalvista Pharmaceuticals (KALV) for $258,337. Following the Form 4 filing with the SEC, Palleiko has control over a total of
Analysis
Price Target
No Data
